BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  AbbVie Plows $205M Upfront Into Alector’s Alzheimer’s Program

  AbbVie announced a strategic collaboration with Alector to develop and commercialize drugs for ALZ’s disease and other neurodegenerative disorders.

  October 24, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Vyaire Inks Huge Lease in Irvine to Expand

  Vyaire Medical, a Chicago-based firm formerly known as CareFusion, is shifting its Orange County base to Irvine from Yorba Linda.

  October 24, 2017

   · 

  1 min read
• 

  Biotech Bay

  NeuroPace Bags $74M to Market Epilepsy Device

  NeuroPace snagged $74M in funding to expand commercialization of its device that treats epileptic seizures.

  October 24, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  BioMidwest

  3 High Potential Low Risk Biotechs Investors Should Watch Out For

  When you think about it, most small biotech companies are odd investments.

  October 24, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  Massachusetts Upstart scPharmaceuticals Files for $100M IPO

  scPharmaceuticals filed recently with the SEC regarding its plans for an IPO.

  October 24, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Biogen Throws Another $200M at Aducanumab With Amended Deal With Neurimmune

  Despite the failures of late stage ALZ’s drugs developed by numerous companies, Biogen seems confident in the future of its amyloid plaque targeting aducanumab.

  October 24, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Gilead Shows Off Mid-Stage NASH Data

  Gilead released results from a Phase II clinical trial of GS-0976 for NASH.

  October 24, 2017

   · 

  2 min read

   · 

  Mark Terry
• Deals

  Catalent Completes Acquisition of Cook Pharmica

  Catalent, Inc. announced it has completed the acquisition of Cook Pharmica LLC, an integrated provider of drug substance and drug product manufacturing and related services.

  October 24, 2017

   · 

  5 min read
• Business

  Palmetto Synthetics Signs CertainT Trademark License Agreement with Applied DNA for Synthetic Fiber Manufacture to Ensure Supply Chain Traceability, Transparency and Trust

  Applied DNA Sciences has signed a new CertainT trademark license agreement with Palmetto Synthetics (“Palmetto”), a leader in the production of high quality, specialty synthetic fiber.

  October 24, 2017

   · 

  4 min read
• Business

  Exact Sciences Reschedules Third-Quarter 2017 Earnings Call to Oct. 30

  EXACT Sciences today announced that the company plans to release its third-quarter 2017 financial results after the close of the U.S. financial markets on Oct. 30.

  October 24, 2017

   · 

  4 min read